Management of atypical chronic lymphocytic leukemia presenting with extreme leukocytosis

Abstract

Abstract Atypical chronic lymphocytic lymphoma (CLL) with CCND1 translocation is poorly described, particularly in the era of modern inhibitors of the B‐cell receptor pathway. We present a patient with atypical CLL who had a significant response to ibrutinib, highlighting the effectiveness of this agent in higher risk CLL subgroups.

Keywords

• Atypical chronic lymphocytic leukemia
• ibrutinib
• leukocytosis